Tapinarof is under clinical development by Dermavant Sciences and currently in Phase II for Palmoplantar Keratoderma. According to GlobalData, Phase II drugs for Palmoplantar Keratoderma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Tapinarof LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tapinarof overview
Tapinarof (Symbiox, Benvitimod, Vtama) is a non-steroidal anti-inflammatory and immunomodulating agent. It is formulated as cream for topical application. Symbiox is indicated for the treatment of adults with mild to moderate stable psoriasis vulgaris. Vtama is indicated for the topical treatment of plaque psoriasis in adults.
Tapinarof (GSK-2894512, WBI-1001, RVT-505, DMVT-505) is under development for the treatment of localized scleroderma, plaque psoriasis and atopic dermatitis. It acts by targeting aryl hydrocarbon receptor (AhR) and Tyrosine-protein kinase Tec. The drug candidate is formulated as a cream and is administered through topical route. The drug candidate is developed based on the symbiochem drug discovery platform. It was also under development for the treatment of atopic dermatitis and plaque psoriasis in China.
For a complete picture of Tapinarof’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
